Oncolytics Biotech Inc. (NasdaqCM: ONCY)
Health Care · Biotechnology · US
$0.87
+2.59% today · -14.6% 1Y
Oncolytics Biotech Inc. (NasdaqCM: ONCY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $107.63M and employs 29 people.
Over the last twelve months the share price has lost 14.6%, trading between 0.73 and 1.51.
Tweenvest scores Oncolytics Biotech Inc. across four factors: quality 21/100. Its strongest factor is quality.
ONCY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $107.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.34
- Dividend yield
- —
- Beta (5Y)
- 1.14
- 52-week high
- $1.51
- 52-week low
- $0.73
- Avg volume (3M)
- —
- Shares outstanding
- 127.51M
- Employees
- 29
- Next earnings
- —
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
- ISIN
- US68237V1035
- Founded
- 1998
- Listed since
- Oct 5, 2001
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.33 | +0.68% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.85 | +0.00% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.80 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.94 | +1.16% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $836.07 | +0.91% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.42 | +13.34% |
Figures last refreshed Aug 18, 2026.